<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558177</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00078317</org_study_id>
    <nct_id>NCT04558177</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Stimulation to Treat Depression and Anxiety in Senior Inpatients</brief_title>
  <official_title>Repetitive Transcranial Stimulation to Treat Depression and Anxiety in Senior Inpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glenrose Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Aging and Brain Health Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many seniors admitted for rehabilitation have symptoms of depression and anxiety that need to&#xD;
      be treated before they can effectively engage in rehabilitation therapy. Anti-depressant or&#xD;
      anti-anxiety medications are often used but there are many reasons why alternative or&#xD;
      adjunctive treatments may be desirable. Medications can take weeks to become effective, if&#xD;
      they work at all. There are many potential side effects of medications, especially in an&#xD;
      older population, including cognitive and other neurologic impairments. There is also an&#xD;
      increasing resistance to a polypharmacy approach to treatment in this population. A low-risk,&#xD;
      relatively non-invasive, easily applied and well-tolerated treatment to accelerate mood and&#xD;
      anxiety disorder resolution would allow earlier and more effective engagement in&#xD;
      rehabilitation therapy. This would in turn shorten lengths of stay and improve quality of&#xD;
      life. Recently, trans-cranial direct current stimulation with 1-2 mA currents has been&#xD;
      proposed as a potential innovative alternative treatment modality. This stimulation is safe,&#xD;
      easy to use, relatively insensitive to electrode placement, and may have other beneficial&#xD;
      cognitive effects. The stimulation device consists of two electrodes placed on either side of&#xD;
      the head, a unit that provides the stimulation and wires that connect this unit to the&#xD;
      electrodes will be used. The electrodes are held in place with a head band.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To determine if using adjunctive TDCS to treat seniors admitted with symptoms of&#xD;
      depression and anxiety reduces length of stay and improves quality of life. Hypothesis: Using&#xD;
      transcranial direct current stimulation (TDCS) will decrease length of stay because it will&#xD;
      reduce symptoms of depression and anxiety enabling patients to engage with their therapy&#xD;
      sooner and more effectively. Justification: Anti-depressant or anti-anxiety medications are&#xD;
      often used for this inpatient population but there are many reasons why alternative or&#xD;
      adjunctive treatments may be desirable. Medications can take weeks to become effective, if&#xD;
      they work at all. There are many potential side effects of medications, especially in an&#xD;
      older population, including cognitive and other neurologic impairments. There is also an&#xD;
      increasing resistance to a polypharmacy approach to treatment in this population. A low-risk,&#xD;
      relatively non-invasive, easily applied and well-tolerated treatment to accelerate mood and&#xD;
      anxiety disorder resolution would allow earlier and more effective engagement in&#xD;
      rehabilitation therapy. This would in turn shorten lengths of stay and improve quality of&#xD;
      life. Objectives: to determine if (1) TDCS reduces symptoms of depression and anxiety and (2)&#xD;
      if patients in the intervention group are discharged from hospital sooner than those in the&#xD;
      sham group. Research Method/Procedure: Direct current of 1.5 milliamp (mA) will be applied&#xD;
      for 20 minutes 5x/week for 3 weeks in a hemispheric montage over the homologous dorso-lateral&#xD;
      prefrontal cortices, anodal on the left. The Glenrose Rehabilitation Hospital is Canada's&#xD;
      largest freestanding rehabilitation institution with programs and services for all age&#xD;
      groups. Rehabilitation services cover all disciplines from physical, occupational therapy to&#xD;
      social work. Older adults are admitted to 3D and 4C to address issues related to frailty such&#xD;
      as weakness and poor balance which affect ability to undertake activities of daily living.&#xD;
      Most of the services they receive as inpatients come from physical and occupational&#xD;
      therapists with speech therapists and psychologists also available if needed.Patients will be&#xD;
      drawn from these seniors admitted to these 2 geriatrics units, 3D and 4C. Candidates who meet&#xD;
      the eligibility criteria and are interested in the project will be approached by the RA who&#xD;
      is not involved in their care and will seek their consent. Patients will be randomized into&#xD;
      standard care (SoC) plus active TDCS and SoC with sham TDCS. TDCS is unique in that effective&#xD;
      double blind sham conditions can be created. Effectiveness of treatment will be judged&#xD;
      primarily on reduced length of stay with improved Geriatric Depression Score (GDS), Geriatric&#xD;
      Anxiety Score (GAS) and Older Person's Quality of Life (OPQOL) as secondary outcome measures.&#xD;
      We expect that it will take ~8 months to complete the study: 3 months for ethics review, 4&#xD;
      months to enroll 100 of a possible 200 eligible patients and 1 for data analysis.&#xD;
&#xD;
      This intervention will be judged primarily on its effect on length of stay for this&#xD;
      population. It is our working hypothesis that this intervention will shorten length of stay&#xD;
      by approximately 5 days. It will do this because TDCS will improve depression (GDS less than&#xD;
      5/15) and anxiety symptoms (score less than 9/30) and thus increase motivation and&#xD;
      engagement. Readiness to proceed with therapy is a clinical judgement based on patient&#xD;
      demeanour and GDS made by the Unit team who will be blind with respect to whether the patient&#xD;
      is receiving TDCS or part of the sham group. Data will include: demographics: gender, age and&#xD;
      diagnosis. Geriatric Anxiety Inventory, Geriatric Depression and Quality of Life scales will&#xD;
      be completed within 1 week of admission, and at ~ 3 and 5 weeks (+3 days) after intervention&#xD;
      initiated. Testing will be coordinated with the Unit Occupational Therapist to avoid&#xD;
      duplication or the risk of over testing.&#xD;
&#xD;
      Data analysis:&#xD;
&#xD;
        1. Baseline group statistics (mean age &amp;, standard deviation, male/female count, diagnostic&#xD;
           frequencies, initial mean &amp; standard deviations of GDS, Geriatric Anxiety Inventory and&#xD;
           Quality of Life scores).&#xD;
&#xD;
        2. Effect of length of stay: Student t test will be used to determine if there is a&#xD;
           significant difference between the 2 groups, defined as p&lt;0.05.&#xD;
&#xD;
        3. Changes in Depression, anxiety or quality of life: significant differences from baseline&#xD;
           at 3 and 5 weeks intervals will be assessed based on minimum clinical differences using&#xD;
           a chi squared test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>sham procedure appears indistinguishable from intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>average length of stay varies from 28 to 42 days</time_frame>
    <description>How long the patient is in hospital measured in days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Score</measure>
    <time_frame>applied within 1 week of admission and then at 3 and 5 weeks</time_frame>
    <description>Survey assessing depression level of subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Anxiety Score</measure>
    <time_frame>applied within 1 week of admission and then at 3 and 5 weeks</time_frame>
    <description>Survey assessing anxiety level of subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Older Person Quality of Life Questionnaire</measure>
    <time_frame>applied within 1 week of admission and then at 3 and 5 weeks</time_frame>
    <description>Survey assessing subject's impression of thier overall quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Geriatric In-patients</condition>
  <arm_group>
    <arm_group_label>Stimulation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive ~1.5mA transcranial stimulation for 20 minutes, 5x per week from a direct current stimulator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device placed only, no stim</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Same as experimental group but the stimulation from the direct current stimulator will be initiated and then stopped</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Direct current stimulator</intervention_name>
    <description>HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.</description>
    <arm_group_label>Device placed only, no stim</arm_group_label>
    <arm_group_label>Stimulation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients above 65 years old&#xD;
&#xD;
          -  a Geriatric Depression Score above 4&#xD;
&#xD;
          -  cognitively sound enough to give consent&#xD;
&#xD;
          -  know English well enough to understand the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  being treated for an infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert Kammerer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alberta Health Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jim V Raso, MASc</last_name>
    <phone>7807357964</phone>
    <email>jim.raso@ahs.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hubert Kammerer, MD</last_name>
    <phone>780-920-4773</phone>
    <email>hubert.kammerer@ahs.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Glenrose Rehabilitation Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5G 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim V Raso, MASc</last_name>
      <phone>7807357964</phone>
      <email>jim.raso@ahs.ca</email>
    </contact>
    <contact_backup>
      <last_name>Hubert Kammerer, MD</last_name>
      <phone>780-920-4773</phone>
      <email>hubert.kammerer@ahs.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://doi.org/10.1016/j.cnp.2016.12.003</url>
    <description>Adverse events of tDCS and tACS: A review. Hideyuki Matsumoto a,â‡‘, Yoshikazu Ugawa. Clinical Neurophysiology Practice 2 (2017) 19-25</description>
  </link>
  <reference>
    <citation>Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29. Review.</citation>
    <PMID>27866120</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We may also use the depression, anxiety and quality of life (QofL) results to look at the effects of direct current stimulation on symptoms of depression and anxiety.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

